Dabrafenib and trametinib exposure-efficacy and tolerance in metastatic melanoma patients: a pharmacokinetic-pharmacodynamic real-life study.

Lauriane GoldwirtB LouveauB BaroudjianC AllayousF JouenneL Da MedaL-T VuH SauvageonF HermsJ DelyonC LebbéS Mourah

Published in: Cancer chemotherapy and pharmacology (2021)

In this study, exposure-efficacy and tolerance analysis highlighted the interest of therapeutic drug monitoring to optimize therapeutic management in BRAFV600mut metastatic melanoma patients based on trough concentrations of dabrafenib and trametinib.

Keyphrases

end stage renal disease
newly diagnosed
chronic kidney disease
peritoneal dialysis
prognostic factors
patient reported outcomes